CONVALESCENT PLASMA THERAPY: A NOVEL APPROACH TO A NOVEL CORONAVIRUS by JOSE, JOICY et al.
Mishra et al. 





CONVALESCENT PLASMA THERAPY: A NOVEL APPROACH TO A NOVEL CORONAVIRUS 
 
JOICY JOSE1, JOHNSON V. BABU1, BHARAT MISHRA2 
1Pharm.D Interns, Nirmala College of Pharmacy, Muvattupuzha. Kerala, 686661, 2Professor and Head, Department of Pharmacology, 
Nirmala College of Pharmacy, Muvattupuzha. Kerala, 686661 
Email: bharatekansh@gmail.com  
Received: 01 Jun 2020, Revised and Accepted: 30 Jun 2020 
ABSTRACT 
Objective: The Corona virus-induced disease-19 (COVID-19) turning to its aggressive phase of spreading, the treatment options where less and 
several options are trialing and seeking. Convalescent plasma therapy is one of the newest trailing therapy for COVID patients today without other 
definite treatment. The convalescent plasma (CP) therapy is used previously and identified its benefits in other conditions. But in the case of COVID 
19 the effects and safety should be ensured for its implementation.  
Methods: Systematically searched in Pub Med and other authentic sources for articles of interest.  
Results: This review includes 5 studies, over all 26 patients who treated CP and following progressions and events. All became clinically better and 
the antibody titer increased in the patients. Not only that the viral load decreased with a reduction in inflammatory markers  
Conclusion: These small studies and case series suggest that CP is effective and safety is high for clinical recover and reduction in viral load. 
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INTRODUCTION 
SARS CoV-2 (Severe acute respiratory syndrome Corona virus-induced 
disease 19) being a pandemic, it first emerged in the wet market of 
Wuhan, China [1]. It is believed that this disease is zoonotic in nature. 
It is a single-stranded RNA (Ribonucleic acid) virus belonging to the β-
coronavirus family [2]. Management of this disease with a proper 
treatment protocol or drug is still a challenging task for scientists and 
physicians. Presently the Convalescent plasma is using in many parts 
of the world, has approved for the clinical trial. The convalescent 
plasma therapy uses antibodies from the blood of a recovered patient 
to treat those critically affected [3]. The therapy can also use to 
immunize those who were at high risk (health workers, families of 
patient’s contacts). It was used for the severe acute respiratory 
syndrome (SARS), pandemic 2009 influenza A (H1N1), avian influenza 
A (H5N1), several hemorrhagic fevers such as Ebola, and other viral 
infections.  
Basic therapy given to patients was monitoring water, electrolyte 
and oxygen rates continuously and other tests like liver enzymes, 
urine routine, arterial blood gas, etc. based on severity. The drugs 
like antiviral, other lifesaving drugs were giving as therapy and 
oxygen in critical cases as supportive care [4]. At there is not an 
antiviral agent that specifically act the target receptor. Therefore the 
importance of convalescent therapy should be discussed [5]. 
Use of convalescent plasma which is an adaptive immunotherapy in 
patients affected with severe acute respiratory syndrome [6]. The 
efficacy and safety of plasma therapy are narrowly understood. Our 
major aim is to clinically analyze the reported studies of plasma 
therapy in patients. 
MATERIALS AND METHODS 
Methodology 
Systematically reviewed the literature published till April 23rd 
regarding Novel and innovative therapies of COVID-19, searched by 
using the keywords COVID-19 therapy, Convalescent plasma therapy, 
Non Antiviral therapies for COVID 19 by using the popular Internet-
based scientific databases such as Science Direct, Pub Med, Springer, 
Scimago, Elsevier including the Newsletters, correspondence articles 
etc. The data analysed of 7 studies from 24 articles obtained from 
PubMed and excluded 2 because of Chinese language. The studies 
include case reports, case series and others. 
The descriptive analysis includes a total of 5 studies, in each study, 
we recorded and evaluated author’s name, publication year, sample 
size, participant’s details, and trail design, duration of follow, 
outcome, results and major findings. 
RESULTS 
Ahn J. et al. 2020 in their study at Korea, introduces two cases of 
corona virus-infected patients who improved their disease condition 
due to the administration of convalescent plasma therapy. In the 
first case, a COVID-19 positive patient with a history of fever and 
cough for the past 12 d was admitted to the hospital. In the initial 
days, he was treated in a local hospital with 400 mg of HCQ 
(Hydroxychlorquine) OD (once daily). Further reports of chest X-ray 
showed mild opacities in the right lower lung, so 400 mg/100 mg of 
lopinavir/ritonavir was included in therapy. Due to the increased 
oxygen demand, he was transferred to a tertiary hospital. 
At the time of admission, he had no complaints of dyspnoea; chest X-
ray showed bilateral infiltration which was rapidly aggravated. Blood 
test shows elevated WBC, CRP, lactic dehydrogenase. After 16 d, ABG 
(Arterial blood gas) analysis showed severe ARDS (Acute respiratory 
distress syndrome) and was treated with IV methylprednisolone 1 
mg/kg/d. On next day CP (500 ml) from a 20 y old male donor who 
had been recovered from COVID-19 infection for the past 21 d. After 
testing of the donor, the plasma was divided into two halves and was 
administered 12 hourly which took one hour each for administration. 
Patient’s condition was improved from next day onwards and did not 
experience any adverse drug reactions. 
Next case introduces an elderly woman with a history of 
hypertension who was found to be COVID-19 positive, treated with 
400 mg hydroxychloroquine sulphate OD and Lopinavir/Ritonavir 
400 mg/100 mg BD. She also experienced a similar condition of the 
above patient and was moved to a tertiary hospital. On the 6th day, 
she was treated with CP from a 20-year-old donor who had been 
recovered 18 d back from COVID-19. She also showed improvement 
in her condition and chest X-RAY also improved. Both tests cases 
showed the positive outcome of the use of a convalescent plasma [7]. 
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Duan k. et al. 2020 conducted a pilot observational study among 
COVID-19 patients with a mean age of 53.4 y who is clinically severe 
patients started convalescent plasma therapy from 11th day of 
admission. Six males and 4 females were included in the study and 4 
had comorbidities. The patients were also treated with antivirals, 
antibiotics, steroids, antifungal and oxygen therapy. The 
convalescent plasma samples taken from 40 recovered patients 
shown that their body contains a high level of antibody titer. The CP 
therapy showed a positive outcome like improvement in clinical 
symptoms and also a reduction in pulmonary lesions. The level of 
neutralizing antibody tires increased and also showed a high level of 
the disappearance of SARS CoV-2 RNA virus in the body. On checking 
with variables of the same age, gender, and severity of the disease, 3 
cases were discharged and 7 cases showed much improvement on 
the discharge process. In the control group, 3 deaths, 6 cases in 
stabilized status and 1 case in improvement status were reported. 
Although 2 patients reported mild adverse drug reactions, no too 
sever adverse drug reactions were reported. Also, there was a 
reduction in laboratory parameters like ASP, ALP, CRP, lymphocyte 
and an increase in the saturation of oxygen. The study confirms the 
efficacy of convalescent plasma in COVID-19 based on its clinical 
effect and severity in terms of safety [8]. 
Shen c. et al. 2020 is a case series of 5 patients who were admitted in 
Shenzhen third people’s hospital, China from January 2020-March 
25, 2020. Each patient received 200-250 ml of convalescent plasma 
i.e.; 400 ml in total from 5 donors between the ages of 18-60 y. A 
total of 5 patients were enrolled in the study with age group 36-73 y 
and two were females. The CP was administered between 10th and 
22nd day of admission. After the CP therapy, one patient becomes 
negative on post-transfusion day and 2 others become negative in 
post day 3. Remaining two became negative after 12 d. The 
inflammatory markers such as CRP, Procalictoin, IL-6 were 
decreased. Only one them had a chronic disease condition and none 
were smoker. All of them become clinically better based on the 
symptoms and radiological examination. None of them reported 
with an adverse drug reaction. These case series conforms the 
efficacy and safety of CP therapy among covid-19 patients [9]. 
Ye M. et al. 2020 conducted their study in six COVID-19 patients who 
were admitted in Huoshenshan hospital from February 11-12th 
march. At the time of admission, all patients were administered with 
drug Arbidol, which is a new antiviral drug. The first patient was 
treated with Levofloxacin for 3 d in a local hospital and his 
temperature became normal. 2nd patient had low oxygen saturation 
and was administered with oxygen therapy. The fourth patient had a 
history of Sjogren syndrome. Convalescent plasma was collected 
from COVID-19 recovered patients who were afebrile for at least 
three days. All the patients received 200 ml of plasma each over 30 
min as an infusion. All patients enrolled were having chest 
abnormalities in CT scan and also their throat swabs were positive. 
Selected patients were from the elderly category expect one who 
was 28 y of age. No serious adverse drug reactions were noticed in 
selected patients. After the treatment with CP, there was a drastic 
improvement in radiology like the resolution of good glass opacities 
and consolidation in all patients except one patient. Two patients 
with coronavirus in throat swab elicited the viral load after the 
therapy (1, 5). Increased anti-SARS CoV-2 titre was noticed in two 
expect one (in 2nd and 3rd patient, not in 1st patient). This study says 
that convalescent plasma treatment showed good efficacy and safety 
in clinical terms for COVID positive patients with improvement in 
their oxygen demand and disease condition [10]. 
Zhang B. et al. 2020 in their case reports, they introduced 4 critically 
ill elderly COVID patients (except one who is 31-year-old pregnant 
female). The first case is of a woman with a history of hypertension, 
her chest X-ray showed bilateral ground-glass opacity. She was 
treated with arbidol 200 mg TID, lopinavir/ritonavir 400 mg BD, 
INF-alpha 50 mcg BD and supportive therapies. Further, due to 
disease progression, she was shifted to the intensive care unit, 
managed with antibiotics and antifungals due to co-infection. She 
was diagnosed with septic shock and chest radiographs showed 
disease progression. A 900 ml of CP was given to the patient in three 
consecutive times i.e.; 200 ml, 300 ml and 400 ml. The patient was 
improved and discharged. 
Second patient was also treated with arbidol 200 mg TID, 
Lopinavir/ritonavir 500 mg BD, and interferon-alpha 2b. His 
condition also became severe, with less oxygen capacity and gave 
mechanical ventilation. The patient was improved and was 
discharged with further treatment of 200 ml CP. Third case of an old 
man with a history of hypertension and CKD, he was treated with 
arbidol 200 mg TID, lopinavir/ritonavir 400 mg BD, oseltamivir 75 
mg BD, ribavirin and INF alpha 5 million units BD. The patient was 
on continuous renal replacement therapy (CRRT). Further, he was 
diagnosed with multiple organ failure, septic shock and treated with 
antifungals. Eight transfusions of 2400 ml of CP was given to the 
patient. In between the CP therapy patient experienced GI bleeding, 
cystorrhagia, pneumorrhagia. Later, viral load decreased at the time 
of discharge. 
Fourth case is of a pregnant female, at the time of admission, she 
experienced severe acute respiratory distress syndrome, multiple 
organ syndrome and septic shock. She underwent invasive 
ventilation and cesarian was done, but the baby died due to 
endouterine asphyxia. When she became stable, she was transferred 
and further investigation showed she had ventricular enlargement 
and decreased systolic function, also she underwent CRRT. She was 
treated with lopinavir/ritonavir 400 mg BD, ribavirin 500 mg 12 
hourly, due to sepsis antibiotics were given. Further, she was 
clinically improved and discharged with 300 ml of CP therapy. All 
these cases indicated the efficacy of CP therapy [11]. 
DISCUSSION 
A total of 26 patients received plasma in various studies, in which 11 
were females. The patients are of mean age 57.9 (SD±13.9). Majority 
of them didn’t have any comorbidity. The patients received 
convalescent plasma as therapy, along with other antivirals and 
other therapies. 
All these cases show the decline in viral load by ELISA and other 
tests within a few days of CP therapy. The antibody titer was found 
to be elevated and highly in the blood of patients after receiving the 
plasma therapy. Not only the significance of antibody and antigen, 
but the clinical symptoms of patients were also reduced and became 
better with evidence of chest radiography. The level of inflammatory 
markers such as CRP, Procalictoin and IL-6 also found to be rapidly 
decreasing. 
The patient who was in critically ill also become better after the 
plasma therapy. The adverse drug reaction (3) found is very less and 
less severe. In COVID-19, without better treatment, plasma therapy 
can be possible. But it should use early as possible, because the 
endogenous Immunoglobulin M and Immunoglobulin G (IgM and 
IgG) generated in peak levels at 2-4 w after the infection. The 
amount of convalescent plasma used in the therapy varied in all 
studies; actually, it is based on patient factors. Also there is a 
significant relation with antiviral, steroids and medication along 
with Plasma therapy. One of the major issue arised when thought 
this kind of therapy was availability of plasma for the treatment. It 
should be with certain standards. In all aspects the therapy is 
successful in small community, but it can’t be taken as a fully 
supported evidence for mass therapy in the community. The long 
term safety as well increased probability rate of secondary infection 
should be studied. As the chances of increased rate of secondary 
infection reported previous week, it should be differentiated in 
terms of blood transfusion. With a rapidly changing situation, the 
aftereffects of coronavirus outbreak may lead more serve in sense 
treatment [12]. 
If the antibody in the blood is preventing or fighting against the 
virus it is possible to isolate the antibody and a futuristic antibody 
compound or vaccine can be generated from this. Its possibility 
also should be studied. The 26 samples is not enough to finalize 
the result. The FDA approved a clinical trial for plasma therapy to 
find out all possible effects and adverse events that can be 
occurred.  
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In the time where all sort of possible treatment options to be explored 
to save the massive loss of human lives all over the world, the 
convalescent plasma has emerged as the brightest ray of hope to save 
the human lives against the COVID-19. The convalescent plasma is 
previously used in other established therapies, but in this situation, it 
has been tried and found to be useful and the practices on various 
centers have proved that it shows the same high level of efficacy and 
safety. A randomized clinical trial should be done to establish or 
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